Abstract
Introduction Endoscopic papillary large balloon dilatation (EPLBD) is an alternative for the treatment of common bile duct (CBD) stones. Existing evidence of factors associated with its outcomes is contradictory. Objective To identify predictors (including the experience of an endoscopist) of success and adverse events in EPLBD. Methods We reviewed the first 200 EPLBD with endoscopic sphincterotomy (EST) performed at our center. Demographic, clinical, and anatomic variables were studied, as well as the performance characteristics, correlating them with individual and group experience. Results Global success was obtained in 87% of cases, and adverse events occurred in 16% of cases. Success was associated with stone size, CBD diameter, and the need to perform mechanical lithotripsy (ML). Despite that adverse events were not univariately associated with any factor, severe adverse events were more likely to occur in stones > 13.5 mm. Multivariate analysis which disclosed success was higher when ML was not required and stones were < 13.5 mm. It also showed that no factor was associated with adverse events or their severity. No differences were found on success or adverse events that could be directly related to experience. Conclusions Success of EPLBD-EST is higher in stones < 13.5 mm and when ML is not required. Experience does not appear to play a major role.
Highlights
Endoscopic papillary large balloon dilatation (EPLBD) is an alternative for the treatment of common bile duct (CBD) stones
Indications for EPLBD-endoscopic sphincterotomy (EST), and endoscopic retrograde cholangiopancreatography (ERCP) data are displayed on Table 2
Seventy-five patients included in this cohort (37.7%) had a previous EST, while in the remaining cases, an EST was performed in the same session of the EPLBD
Summary
Endoscopic papillary large balloon dilatation (EPLBD) is an alternative for the treatment of common bile duct (CBD) stones. It showed that no factor was associated with adverse events or their severity. Treatment of common bile duct (CBD) stones is, at present time, the most frequent indication to perform endoscopic retrograde cholangiopancreatography (ERCP) in Western countries [1]. For this purpose, we have a variety of endoscopic techniques of proven efficacy. EPLBD was initially developed under the hypothesis that it could potentially be less traumatic than EST to the major papilla, and it could be associated with fewer adverse events [3]. Initial studies showed that EPLBD was associated with less bleeding but an increased risk of acute pancreatitis [4, 5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.